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Poster Session I 49stimulated with autologous LCL with or without MSC for 5 days.
The percentage of EBV-pentamer specific CTL was not affected
by the presence of MSC (mean 1.59% vs 1.52%). MSC did not in-
hibit IFN-g production by EBV-CTL (6039 6 1644 vs 5885 6
1608). Furthermore, cytolytic killing of LCL by EBV-CTL was
not suppressed by MSC (mean specific lysis 47 6 3.6% vs 52 6
4.7% at E:T ratio 30:1). Finally, we studied anti-CMV immunity
in 2 patiens who receivedMSC for acute GVHDof the gut evolving
into chronic GVHD, with a good transient response. PBMC from
these patients showed persistence of pp65-pentamer positive T-
cells and retained IFN-g response to CMV post MSC infusion
(mean SFC 91/105 PBMC pre-MSC, 113 at 2 weeks and 221 at 1
month post MSC infusion). Conclusion: MSC have little effect
on T-cell responses to CMV, EBV and Ad, which contrasts to their
strong immunosuppressive effects on alloreactive T-cells. These
data have major implications for immunotherapy of GVHD with
MSC and suggest that the effector functions of virus-specificT-cells
may be retained after MSC infusion.
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MAINTAININGTHE IN-VIVOHEMATOPOIETICNICHE IN-VITRO; ANOVEL
APPROACH TO STUDYING HEMATOPOEISIS IN BOTH A MURINE AND
A LARGE ANIMAL SYSTEM
Kraft, D.L., Smith, A., Weissman, I.L. Stanford University School of
Medicine, Stanford, CA; DRFV Foundation.
Introduction: INTRO: Hematopoietic Stem Cells (HSC) are
the most extensively characterized stem cell, yet understanding of
their niche, and the ability to maintain and expand HSCs in-vitro
remains a challenge. In vitro study of HSC has generally been lim-
ited to well-based cultures, or use of 3D structures, supplemented
with cytokines. As apposed to constructing an artificial niche, we
sought to examine whether the existent hematopoietic niche could
be maintained in-vitro and support HSC in-vitro, both in murine
long bones marrow fragments, & in perfused large animal vertebrae
and bone marrow cores. Methods: Femur and tibia from 3 month
old mice were harvested, and sectioned into 1/3rds ends removed to
facilitate perfusion of the bone marrow fragments (BMF). In addi-
tion, whole marrow ‘plugs’ were flushed from tibia. These were
then cultured in normal or low O2, in regularly changed media
1/- cytokines (Flt2, SCF, TPO). BMF were removed over time,
and analyzed by CFU assay and FACS for presence of HSC, &
transplanted into sublethally irradiated Ly5.2 recipients.
Large animal model: Fresh thoracic and lumbar vertebrae from
large juvenile swine were harvested and separated, then maintained
in culture as: non-perfused in media, syringe perfused by pump
from 0.5 to 1.5 ml/hr of media, or by surgically cannulated vertebral
artery and vein and maintained on a bioreactor. Vertebrae under-
went core biopsies every 1–2 days and were analyzed for viability
and by histology. Results: Murine BMF contained 35–72% viable
cells as measured by trypan blue exclusion at up to 14 days. In 4
to 11 day old BMF, a population of Slam1, KLS cells were detect-
able. In BMF transplanted recipients, donor derived cells were de-
tectable .4 months post transplant. Mean donor granulocyte
engraftment from BMF was 5.2 to 22.1%, compared to 19% from
an control BM cells, suggesting long-term engraftment was derived
from HSC maintained within cultured BMF. In porcine vertebral
bodies, non-perfused vertebrae had\10% viability by day 4 com-
pared to 20% viability if perfused by pump at .5 ml/hr or 49% via-
bility when perfused at .1 ml/hr. Histology revealed maintained
marrow structure and healthy appearing cells in marrow cores
from perfused vertebrae in contrast to unperfused marrow samples.
Conclusion:These results suggest that the intrinsicHSC niche can
be maintained in-vitro and further optimization of this approach
may provide a novel means to study murine and eventually human
HSC and niche in-vitro.
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ESTABLISHMENT OF BONE MARROW STROMA FROM PATIENTS AT PRE
AND POST-MOBILIZATION FOR AUTOLOGOUS PERIPHERAL BLOOD
STEM CELLS TRANSPLANTATION
Schimieguel, D.M.2, Silva, L.1, Dominato, J.A.3, Silva, M.R.R.4,
Nader, H.B.3, Borelli, P.5, Souza, M.K.2, Oliveira, J.S.R.2 1The Uni-versity of Texas MDAnderson Cancer Center, Houston, TX; 2University
Federal of Sao Paulo, Sao Paulo, Brazil; 3University Federal of Sao
Paulo, Sao Paulo, Brazil; 4University Federal of Sao Paulo, Sao Paulo,
Brazil; 5University State of Sao Paulo, Sao Paulo, Brazil.
Objective: Successful of autologous peripheral blood stem cell
transplantation relies on mobilization’s capacity of hematopoetic
progenitor cells frommarrow to blood stream.The aim of this study
was to evaluate the correlation between the velocity of establish-
ment and maintenance marrow’s stroma in vitro from mononuclear
cells and bone marrow biopsy data obtained before and after mobi-
lization treatment in hematologicmalignancies and controls.Mate-
rials and Methods: Were evaluated clinical data from 22 patients
and 10 healthy donors as controls regarding the velocity of estab-
lishment and maintenance of stroma through long-term bone mar-
row culture on semisolid medium and bone marrow
histopathological features. Results: Out of 32 samples harvested
at pre-mobilization, 21 (66%) achieve $70% confluency while 11
of 27 samples (34%) could do so after mobilization. At pre-mobili-
zation, 91% of samples that did not achieve confluency were from
patients. After mobilization, 9 (82%) and 2 (18%) samples from pa-
tients and controls reached confluency, respectively, indicating a re-
duction of stroma establishment potential, especially from controls
(p 5 0.03). We could not observe any difference between ‘‘good’’
and ‘‘poor’’ mobilizer in both times.Nevertheless, the velocity of es-
tablisment was faster from the controls than patients.Conclusions:
Patients with fibrotic or poor cellularity demonstrated lower capac-
ity of stroma’s establishing suggesting that damage might affect
most probably the marrow microenvironment than the hematopoi-
etic progenitors. However, a more reduction of stroma establish-
ment capacity disclosed in controls than patients after
mobilization might be due to a more intense mobilization in these
settings.HISTOCOMPATIBILITY/ALTERNATIVE
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DOUBLE UMBILICAL CORD BLOOD TRANSPLANTATIONWITH REDUCED
INTENSITY CONDITIONING AND SIROLIMUS-BASED GVHD PROPHY-
LAXIS
Cutler, C.1, Kao, G.1, Ho, V.1, Alyea, E.1, Koreth, J.1, Armand, P.1,
Dey, B.2, Spitzer, T.2, Soiffer, R.1, Antin, J.H.1, Ballen, K.2 1Dana-
Farber Cancer Institute, Boston, MA; 2Massachusetts General Hospital,
Boston, MA.
Single-unit umbilical cord blood transplantation (UCBT) in
adults is associated with high transplant-related mortality, largely
due to delayed engraftment and infection. Double UCBT
(DUCBT) is associated with faster engraftment, but also with
high rates of acute GVHD. We studied DUCBT using sirolimus
and tacrolimus to improve GVHD outcomes.
Methods: Conditioning consisted of fludarabine (30 mg/m2 
6), melphalan (100 mg/m2  1), and rabbit ATG (1.5 mg/kg  4).
UCB units were $4/6 HLA-A, B, DR allele-matched with each
other and the recipient, and contained a minimum combined dose
of 3.7  107 TNC/kg pre-cryopreservation. GVHD prophylaxis
was tacrolimus (5–10 ng/ml) and sirolimus (3–12 ng/ml). Results:
29 patients (median 49 years, range 19–67) with .100 day follow-
up are reported. Diagnoses include AML(8), NHL(7), HD(5),
MDS(4), CLL/PLL(2), ALL(1), MPD (1) and CML(1). The me-
dian total cell doses prior to cryopreservation were 5.2  107
TNC/kg (range 3.7–7.6  107) and 12.5  106 CD341 cells (range
1.5–29.0 106). Neutrophil engraftment occurred at amedian of 21
days (range 13–70) and platelet engraftment occurred at a median of
42 days (range 25–162) after DUCBT. Three subjects did not attain
platelet transfusion independence by day 100 and there were 3 late
graft failures. 3 patients developed Gr. II-IV acute GVHD (2 Gr. II
and 1 Gr. III, median 21 days). Acute GVHD was less frequent
when compared with a prior DUCBT cohort that received cyclo-
sporine and MMF as GVHD prophylaxis (10.3% vs. 36.9%, p 5
0.04). Only 2 patients developed chronic GVHD after DUCBT.
